論文 - 山上　亘

Durvalumab plus carboplatin/paclitaxel followed by durvalumab with or without olaparib as first-line treatment for newly diagnosed advanced or recurrent endometrial cancer: Japan subset from the phase III DUO-E trial

Nishio S, Nishikawa T, Mori M, Kamiura S, Sumi T, Yunokawa M, Imai Y, Kondo E, Takehara K, Takano H, Kudaka W, Kado N, Yamagami W, Kato H, Nishino K, Usami T, Hamanishi J, Nii M, Takaya I, Okamoto A

Journal of gynecologic oncology 36 （ 4 ） e118 2025年07月

研究論文（学術雑誌）, 共著,  ISSN  2005-0380

• Access to Document (DOI)

Prognostic significance of para-aortic node metastasis in endometrial cancer: Japanese Gynecologic Oncology Group Study JGOG2043 post hoc analysis

Konno Y, Mayama M, Takehara K, Yokoyama Y, Suzuki J, Susumu N, Harano K, Nakagawa S, Nakanishi T, Yamagami W, Yoshihara K, Nomura H, Okamoto A, Aoki D, Watari H

J Gynecol Oncol 36 （ 4 ） e57 2025年07月

研究論文（学術雑誌）, 共著

High-Throughput Drug Screening of Clear Cell Ovarian Cancer Organoids Reveals Vulnerability to Proteasome Inhibitors and Dinaciclib and Identifies AGR2 as a Therapeutic Target

Yoshimura T, Kamatani T, Ookubo A, Takahashi M, Itoh M, Ebisudani T, Masugi Y, Toyonaga T, Hamamoto J, Saotome K, Sakai K, Yoshihama T, Moritoki N, Shibata S, Yasuda H, Sato T, Sato TA, Aoki D, Yamagami W, Tsunoda T, Chiyoda T

Cancer research communications 5 （ 6 ） 1018 - 1033 2025年06月

研究論文（学術雑誌）, 共著

• Access to Document (DOI)

Advancing Precision Oncology: Whole-Exome Sequencing in Endometrial Cancer Liquid-Based Cytology

Takamatsu R, Nakamura K, Chiyoda T, Tsuji K, Kawano R, Yoshimi N, Yamagami W, Nishihara H

Arch Pathol Lab Med 149 （ 6 ） 561 - 567 2025年06月

研究論文（学術雑誌）, 共著

LCN2-mediated ferroptosis resistance in tissue homeostasis and early-stage tumorigenesis of the fallopian tube epithelium

Imaeda K, Tamura T, Nagai S, Sugihara E, Yamasaki J, Otsuki Y, Nakamura K, Takeda T, Nakamura K, Nogami Y, Tsuji K, Chiyoda T, Kisu I, Kobayashi Y, Banno K, Yamaguchi R, Sakurada K, Saya H, Aoki D, Ahmed AA, Nagano O, Masuda K, Yamagami W

iScience 28 （ 6 ） 112654 - 112654 2025年06月

研究論文（学術雑誌）, 共著

Next-generation sequencing outperforms Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE) in endometrial cancer molecular classification

Yoshimura T, Nakamura K, Chiyoda T, Takamatsu R, Kawano R, Aimono E, Kawaida M, Sakai K, Masugi Y, Nishihara H, Yamagami W

BJC Rep 3 （ 1 ） 37 - 37 2025年05月

研究論文（学術雑誌）, 共著

Prognostic impact of peritoneal cytology on treating endometrial cancer using data from the Japan Society of Obstetrics and Gynecology cancer registry

Sakai K, Yamagami W, Takahashi F, Tokunaga H, Yamamoto E, Yokoyama Y, Yoshino K, Kawana K, Nagase S

J Gynecol Oncol 36 （ 3 ） e41 - e41  2025年05月

研究論文（学術雑誌）, 共著

CXCL9 and CXCL13 shape endometrial cancer immune-activated microenvironment via tertiary lymphoid structure formation

Nagase Y, Kodama M, Aimono E, Nakamura K, Takamatsu R, Abe K, Yoshimura T, Chiyoda T, Yamagami W, Nishihara H

Cancer Sci 116 （ 5 ） 1193 - 1202 2025年05月

研究論文（学術雑誌）, 共著

mTOR-mediated p62/SQSTM1 stabilization confers a robust survival mechanism for ovarian cancer

Tamura T, Nagai S, Masuda K, Imaeda K, Sugihara E, Yamasaki J, Kawaida M, Otsuki Y, Suina K, Nobusue H, Akahane T, Chiyoda T, Kisu I, Kobayashi Y, Banno K, Sakurada K, Okita H, Yamaguchi R, Ahmed AA, Yamagami W, Saya H, Aoki D, Nagano O

Cancer Lett 616   217565 - 217565 2025年04月

研究論文（学術雑誌）, 単著

難治性のほてり・発汗に対して補腎剤が著効した3症例

横田めぐみ，椎名美季，大野あゆみ，谷本慧子，堀場裕子，山上 亘

産婦人科漢方研究のあゆみ 40   58 - 62 2025年04月

研究論文（学術雑誌）, 共著

めまいを訴える更年期女性への漢方処方と効果

椎名美季，横田めぐみ，大野あゆみ，谷本慧子，堀場裕子，山上 亘

産婦人科漢方研究のあゆみ 40   26 - 30 2025年04月

研究論文（学術雑誌）, 共著

横紋筋融解症を発症し早産に至った筋強直性ジストロフィー合併妊娠の1例

山田 郁，大谷利光，緒方泰彦，石川直嗣，梶川かおる，秋田啓介，玉井順子，田中雄也，春日義史，池ノ上 学，山上 亘，田中 守

東京産科婦人科学会会誌 74 （ 2 ） 367 - 370 2025年04月

共著, 査読有り

Immunotherapy for endometrial cancer

Wada M, Yamagami W

Int J Clin Oncol 30 （ 3 ） 449 - 456 2025年03月

研究論文（学術雑誌）

子宮内膜異型増殖症に対する鏡視下子宮全摘出術前における、子宮内膜全面掻爬術の有用性に関する検討

坂巻智美，吉村拓馬，落合大輔，地阪光代，平田 桃，高橋美央，坂井健良，和田美智子，千代田達幸，山上 亘，田中 守

東京産科婦人科学会会誌 74 （ 1 ） 8 - 12 2025年01月

研究論文（学術雑誌）, 共著, 査読有り

Delayed and immediate cutaneous adverse events during pembrolizumab combination chemotherapy against cervical cancer: Case series

Adachi T., Matsui T., Okata-Karigane U., Takahashi C., Tahara U., Hyodo M., Miyagawa A., Kobayashi K., Nakamura Y., Funakoshi T., Nishio H., Yamagami W., Takahashi H.

Journal of Dermatology 52 （ 1 ） 132 - 137 2025年01月

研究論文（学術雑誌）, 共著,  ISSN  03852407

　概要を見る

Immune checkpoint inhibitors (ICIs), such as pembrolizumab (PEM), are widely recognized for their antitumor efficacy, but they can also lead to various cutaneous adverse events (CAEs). While most CAEs can be managed with topical corticosteroids, severe cases may necessitate halting immunotherapy. The incidence of severe CAEs is notably higher in combination therapies involving ICIs than in monotherapies, emphasizing the need for stringent, long-term management strategies. This includes potential modifications or discontinuations of the combination therapy. PEM, when added to the conventional paclitaxel + cisplatin (or carboplatin) ± bevacizumab regimen, has shown significant improvements in overall and progression-free survival for patients with Stage IVB metastatic or locally uncontrolled recurrent cervical cancer. This case series retrospectively examined the incidence and management of CAEs in 19 female patients treated with this combination therapy between October 2022 and May 2023. Four patients exhibiting CTCAE grade 3 were identified. The four cases of severe CAEs involved erythema multiforme after the initial course of PEM combination chemotherapy. Notably, three patients experienced immediate hypersensitivity reactions, including anaphylaxis, during subsequent treatments. This observation underscores the necessity for rigorous dermatological monitoring of patients undergoing PEM combination chemotherapy. Such vigilance is crucial for early detection of adverse reactions and timely adjustment of treatment regimens, thereby enhancing patient safety.

• Access to Document (DOI)

Transcriptome Concordance Between Borderline Tumors and Endometrioid Carcinoma: An Integrative Genomic Analysis

Takahashi M, Nakamura K, Chiyoda T, Okada C, Nohara S, Takamatsu R, Yanazume S, Kobayashi H, Nishihara H, Yamagami W

Cancer Med 14 （ 2 ） e70601 - e70601 2025年01月

研究論文（学術雑誌）, 共著

Prognostic impact of the number of resected pelvic nodes in endometrial cancer: Japanese Gynecologic Oncology Group Study JGOG2043 post hoc analysis

Konno Y, Mayama M, Takehara K, Yokoyama Y, Suzuki J, Susumu N, Harano K, Nakagawa S, Nakanishi T, Yamagami W, Yoshihara K, Nomura H, Okamoto A, Aoki D, Watari H

J Gynecol Oncol 36 （ 1 ） e3 - e3 2025年01月

研究論文（学術雑誌）, 共著

Safe Implementation of Robotic Surgery for Gynecologic Diseases at a Tertiary Center: Retrospective Analysis of 149 Cases and Review of the Literature

Yoshimura T, Nishio H, Sakai K, Nogami Y, Hayashi S, Yamagami W

Gynecol Minim Invasive Ther 14 （ 1 ） 33 - 39 2024年12月

研究論文（学術雑誌）

The SCRUM-MONSTAR Cancer-Omics Ecosystem: Striving for a Quantum Leap in Precision Medicine.

Hashimoto T, Nakamura Y, Fujisawa T, Imai M, Shibuki T, Iida N, Ozaki H, Nonomura N, Morizane C, Iwata H, Okano S, Yamagami W, Yamazaki N, Kadowaki S, Taniguchi H, Ueno M, Boku S, Oki E, Komatsu Y, Yuki S, Makiyama A, Otsuka T, Hara H, Okano N, Nishina T, Sakamoto Y, Miki I, Kobayashi S, Yuda J, Kageyama SI, Nagamine M, Sakashita S, Sakamoto N, Yamashita R, Koga Y, Bando H, Ishii G, Kuwata T, Park WY, Ohtsu A, Yoshino T

Cancer discovery 14 （ 11 ） 2243 - 2261 2024年11月

ISSN  2159-8274

• Access to Document (DOI)

術中迅速病理診断で類内膜癌G1/G2,筋層浸潤1/2未満の子宮体癌に対して骨盤リンパ節郭清は必要か?

吉村拓馬，坂井健良，落合大輔，坂巻智美，地阪光代，高橋美央，吉浜智子，千代田達幸，田中 守，山上 亘

関東連合産科婦人科学会誌 61 （ 4 ） 479 - 484 2024年11月

研究論文（学術雑誌）, 共著